Trials / Unknown
UnknownNCT04334330
Palbociclib, Trastuzumab,Pyrotinib and Fulvestrant Treatment in Patients With Brain Metastasis From ER/PR Positive, HER-2 Positive Breast Cancer: A Multi-center, Prospective Study in China
Palbociclib, Trastuzumab, Pyrotinib and Fulvestrant Treatment in Patients With Brain Metastasis From ER/PR Positive, HER-2 Positive Breast Cancer: A Multi-center, Prospective Study in China
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 34 (estimated)
- Sponsor
- Sun Yat-sen University · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to evaluate the efficacy of combination of palbociclib, trastuzumab and pyrotinib with fulvestrant in ER/PR positive and HER2-positive breast cancer patients with brain metastasis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Palbociclib, Trastuzumab, Pyrotinib and Fulvestrant | ER/PR positive, HER2-positive breast cancer patients with brain metastatic lesions receive palbociclib PO daily on days 1-21, combined with trastuzumab IV every three weeks, pyrotinib PO daily and fulvestrant IM every 4 weeks. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. |
Timeline
- Start date
- 2020-12-04
- Primary completion
- 2023-12-30
- Completion
- 2024-12-31
- First posted
- 2020-04-06
- Last updated
- 2022-05-02
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04334330. Inclusion in this directory is not an endorsement.